Article
Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
Human gene therapy - 1 Jan 2007
Kanai Ryuichi, Tomita Hideyuki, Hirose Yuichi, Ohba Shigeo, Goldman Steven, Okano Hideyuki, Kawase Takeshi, Yazaki Takahito
Abstract excerpt
Although second-generation replication-conditional herpes simplex virus type 1 (HSV-1) vectors defective for both ribonucleotide reductase (RR) and the virulence factor gamma(1)34.5 have been proven safe through a number of animal experiments and clinical trials, their therapeutic efficacy was also markedly reduced. To overcome this situation, we concentrated on the use of a tumor-specific promoter in this study,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.